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Background: MicroRNAs (miRNAs) are short, non-coding RNAs (~22 nt) that play important roles in the
pathogenesis of human diseases by negatively regulating gene expression. Although miR-196a has been implicated
in several other cancers, its role in non-small cell lung cancer (NSCLC) is unknown. The aim of the present study
was to examine the expression pattern of miR-196a in NSCLC and its clinical significance, as well as its biological
role in tumor progression.
Methods: Expression of miR-196a was analyzed in 34 NSCLC tissues and five NSCLC cell lines by quantitative
reverse-transcription polymerase chain reaction (qRT-PCR). The effect of DNA methylation on miR-196a expression
was investigated by 5-aza-2-deoxy-cytidine treatment and bisulfite sequencing. The effect of miR-196a on
proliferation was evaluated by MTT and colony formation assays, and cell migration and invasion were evaluated by
transwell assays. Analysis of target protein expression was determined by western blotting. Luciferase reporter
plasmids were constructed to confirm the action of miR-196a on downstream target genes, including HOXA5.
Differences between the results were tested for significance using Student’s t-test (two-tailed).
Results: miR-196a was highly expressed both in NSCLC samples and cell lines compared with their corresponding
normal counterparts, and the expression of miR-196a may be affected by DNA demethylation. Higher expression of
miR-196a in NSCLC tissues was associated with a higher clinical stage, and also correlated with NSCLC lymph-node
metastasis. In vitro functional assays demonstrated that modulation of miR-196a expression affected NSCLC cell
proliferation, migration and invasion. Our analysis showed that miR-196a suppressed the expression of HOXA5 both
at the mRNA and protein levels, and luciferase assays confirmed that miR-196a directly bound to the 3’untranslated
region of HOXA5. Knockdown of HOXA5 expression in A549 cells using RNAi was shown to promote NSCLC cell
proliferation, migration and invasion. Finally, we observed an inverse correlation between HOXA5 and miR-196a
expression in NSCLC tissues.
Conclusions: Our findings indicate that miR-196a is significantly up-regulated in NSCLC tissues, and regulates
NSCLC cell proliferation, migration and invasion, partially via the down-regulation of HOXA5. Thus, miR-196a may
represent a potential therapeutic target for NSCLC intervention.
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Non-small cell lung cancer (NSCLC) including adeno-
carcinoma and squamous cell carcinoma, is the predom-
inant form of lung cancer, and accounts for the majority
of cancer deaths worldwide [1]. Despite recent advances
in clinical and experimental oncology, the prognosis of
lung cancer is still unfavorable, with a 5-year overall sur-
vival rate of approximately 11% [2]. Thus, a detailed
understanding of the mechanisms underlying NSCLC
development and progression are essential for improving
the diagnosis, prevention and treatment of this disease.
Recently, accumulating evidence has shown that non-
coding small RNAs may be involved in NSCLC patho-
genesis, providing new insights into disease biology.
MicroRNAs (miRNAs) are 21–24 nucleotide, small,
non-coding RNAs that regulate gene expression by base
pairing with target mRNAs in the 3′-untranslated region
(3′-UTR), leading to mRNA cleavage or translational re-
pression [3,4]. Dysregulation of miRNAs may lead to
alterations in cellular differentiation, proliferation and
apoptotic processes that are important in the develop-
ment of cancer [5,6]. Indeed, deregulation of miRNAs is
closely associated with tumor initiation, promotion and
progression via the regulation of key oncogenes or
tumor suppressors [7,8]. Thus, elucidating the biological
consequences of miRNA dysregulation and identifying
miRNA targets are critical for a complete understanding
of miRNA pathways and their underlying molecular
mechanisms.
The mature miR-196a is transcribed from two miR-
196a genes, miR-196a-1 and miR-196a-2. Recently,
miRNA profiling studies indicate that miR-196a is
overexpressed in several tumor tissues, including
NSCLC [9-12]. Furthermore, an increasing number of
reports indicate that miR-196a plays important roles in
development, immunity and tumor pathogenesis via the
targeting of specific genes [13-17]. In this study, we
demonstrate that increased miR-196a expression is a
characteristic molecular change in NSCLC and investi-
gate the effect of increased miR-196a levels on the
phenotypes of NSCLC cell lines. We also show that
miR-196a may function as an oncogene by directly
targeting HOXA5.
Methods
Patient and tissue samples
Paired NSCLC and adjacent non-tumor lung tissues
were obtained from 34 consecutive patients who under-
went primary surgical resection of NSCLC with
informed consent between 2006 and 2007 at First
Affiliated Hospital of Nanjing Medical University, China.
Surgically laser capture micro-dissected NSCLC and ad-
jacent normal tissues were immediately snap-frozen in
liquid nitrogen and stored at −80°C until total RNA wasextracted. Tumor samples were at least 80% composed
of viable-appearing tumor cells on histological assess-
ment. The pathological stage, grade, and nodal status
were appraised by an experienced pathologist. Clinico-
pathologic characteristics including tumor-node-
metastasis (TNM) staging had been collected. The study
was approved by the Research Ethics Committee of Nan-
jing Medical University, China.
Cell lines and culture conditions
Four NSCLC adenocarcinomas cell lines (A549, SPC-A1,
NCI-H1650, NCI-H1299) , a NSCLC squamous carcin-
omas cell line (SK-MES-1), a normal human bronchial
epithelial cell line (16HBE), and a human embryonic kid-
ney cell line (HEK293T) were purchased from the Insti-
tute of Biochemistry and Cell Biology of the Chinese
Academy of Sciences (Shanghai, China). Cells were cul-
tured in RPMI 1640 or DMEM (GIBCO-BRL) medium
supplemented with 10% fetal bovine serum (10% FBS),
100 U/ml penicillin, and 100 mg/ml streptomycin (invi-
trogen) in humidified air at 37°C with 5% CO2.
RNA extraction and qRT-PCR analyses
Total RNA was isolated with TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
protocol. qRT-PCR assays were performed to detect
miR-196a and HOXA5 expression using the PrimeScript
RT reagent Kit and SYBR Premix Ex Taq (TaKaRa,
Dalian, China) according to the manufacturer’s
instructions.
The relative level of miR-196a was determined by
qRT-PCR using gene specific primers. U6 was vali-
dated as the normalizer, since which expression
showed minimal variation in different cell lines and
cancer specimens. The RT primers were designed as
follows: miR-196a, 5’ GTCAGAAGGAATGATGCA
CAGCCAACAACA 3’ and U6, 5’ AACGCTTCACG
AATTTGCGT 3’. The RT reaction was carried out
under the following conditions: 42°C for 15 min; 85°C
for 5 sec; and then held on 4°C. After the RT reaction,
the complementary DNA products were diluted at
1:100, and 1ul of the diluted complementary DNA was
used for subsequent qRT-PCR reactions.
The PCR primers for mature miR-196a or U6
were designed as follows: miR-196a sense, 5’
CGTCAGAAGGAATGATGCACAG 3’ and reverse, 5’
ACCTGCGTAGGTAGTTTCATGT 3’; U6 sense, 5’
CTCGCTTCGGCAGCACA 3’ and reverse, 5’
AACGCTTCACGAATTTGCGT 3’. The PCR reaction
was conducted at 95°C for 30 s and followed by 40
cycles of 95°C for 5 s and 60°C for 34 s in the ABI 7500
real-time PCR system (Applied Biosystems, Foster City,
CA, USA). The qRT-PCR results were analyzed and
expressed as relative miRNA expression of CT
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fold changes.
For analysis of HOXA5 mRNA expression, 100 ng
total RNA was reverse transcribed in a final volume of
10 μl using random primers under standard conditions.
HOXA5-specific primers were designed as follows:
sense, 5’ TCTCGTTGCCCTAATTCATCTTTT3’ and
reverse, 5’ CATTCAGGACAAAGA GATGAACAGAA
3’. To verify integrity of HOXA5 expression, GAPDH
gene was used as an internal control and the sequences
of primers were as follows: sense, 5’ GGGAGC
CAAAAGGGTCAT 3’ and reverse, 5’ GAGTCCTTC
CACG ATACCAA 3’. The relative levels of HOXA5
mRNA were calculated based on the difference between
amplification of HOXA5 and GAPDH mRNA using the
2-Δct method. All experiments were performed three
times with three technical replicates.
CpG island identification and methylation analysis
Using the CpG Island Searcher Web tool (http://www.
ebi.ac.uk/Tools/emboss/ cpgplot/index.html), a CpG is-
land was identified upstream (−500 bp) of the region en-
coding miRNA-196a-1. For determination of the
methylation status of the CpG island, genomic DNA
prepared from 16HBE cells, was modified by sodium
bisulfite (EZ DNA Methylation Kit , Zymo Research),
followed by PCR using the sense primer 5’ TTTTTTAG
GATAGGAGGGGAT 3’ and reverse, 5’ TCTAAATCCT
TAACCCC CTAAC 3’, respectively. PCR-amplified
product was transformed into E.coli DH5α cells. Subse-
quently obtained plasmids were subjected to sequencing.
Treatment of 16HBE cells with 5-aza-2-deoxy-cytidine
(5-aza-CdR)
16HBE cells (2.5 × 105) were seeded into six-well culture
plate on day 0 and exposed to 0, 2 or 5 μM 5-aza-CdR
(Sigma-Aldrich)for day 1 to day 3. Thereafter, the cells
treated with 5-aza–CdR were harvested on day 3 and
used for detection of miR-196a expression or methyla-
tion analysis.
Transfection of NCSCL cells
All plasmid vectors (pCDNA/miR-196a and pCDNA/
miR-NC ) for transfection were extracted by DNA Midi-
prep or Midiprep kit (Qiagen, Hilden, Germany). Mature
miR-196a mimics and miR-196a inhibitors (Anti-miR-
196a) were purchased from Sigma-Aldrich and Applied
Biosystems, AB, Ambion, respectively. The appropriate
negative controls (miR-NC or anti-miR-NC) were
synthesized by GenePharma, Shanghai, China. HOXA5-
siRNA named si-HOXA5 and non-specific control
siRNA (si-NC) were purchased from genechem, Shang-
hai, China. The pCDNA/miR-196a, mature miR-196a
mimics or si-HOXA5 was transfected into culturedA549 cells respectively, and miR-196a inhibitors were
transfected into cultured SPC-A1 cells. A549 or SPC-A1
cells were grown on six-well plate to confluence and
transfected using Lipofectamine2000 (Invitrogen)
according to the manufacturer’s instructions. Fourty-
eight hours after transfection, cells were harvested for
qRT-PCR analyses or Western blot.
Cell proliferation assays
Cell proliferation was monitored using Cell Proliferation
Reagent Kit I (MTT) (Roche Applied Science). MiR-
196a inhibitors transfected SPC-A1 cells (3000/well),
and pCDNA/miR-196a or si-HOXA5 transfected A549
cells (2000/well) were allowed to grow in 96-well plates.
Cell proliferation was documented every 24 h following
the manufacturer’s protocol. All experiments were per-
formed in quadruplicate. For the colony formation assay,
a total of 500 miR-196a inhibitors transfected SPC-A1,
pCDNA/miR-196a or si-HOXA5 transfected A549 cells
were placed in a fresh six-well plate and maintained in
media containing 10% FBS, replacing the medium every
4 days. After 14 days, cells were fixed with methanol and
stained with 0.1% crystal violet (sigma). Visible colonies
were manually counted. Triplicate wells were measured
in each treatment group.
Flow-cytometric analysis of apoptosis
SPC-A1 cells transiently transfected with miR-196a inhi-
bitors or anti-miR-NC, were harvested at 48 h after
transfection by trypsinization. After the double staining
with FITC-Annexin V and Propidium iodide (PI), the
cells were analyzed with a flow cytometry (FACScanW;
BD Biosciences) equipped with a CellQuest software
(BD Biosciences) [18]. Cells were discriminated into vi-
able cells, dead cells, early apoptotic cells, and apoptotic
cells, and then the relative ratio of early apoptotic cells
were compared to control from each experiment. All of
the samples were assayed in triplicate.
Hoechst staining assay
SPC-A1 cells transfected with miR-196a inhibitors were
cultured in six-well plates, and were incubated with
Hoechst 33342 solution (50 ng/ml, Sigma, St Louis, MO,
USA) for 10 min at room temperature. Cells were then
washed twice with PBS and changes in nuclear morph-
ology were detected by fluorescence microscopy using a
filter for Hoechst 33342 (365 nm). For quantification of
Hoechst 33342 staining, the percentage of Hoechst
-positive nuclei per optical field (at least 50 fields) was
counted in three independent experiments.
Cell migration and invasion assays
For the migration assays, 24 h after transfection, 5 × 104
cells in serum-free media were placed into the upper
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the invasion assays, 1 × 105 cells in serum-free media
were placed into the upper chamber of an insert coated
with Matrigel(Sigma-Aldrich, USA). Media containing
10% FBS were added to the lower chamber. After several
hours of incubation, the cells remaining on the upper
membrane were removed with cotton wool, whereas the
cells that had migrated or invaded through the mem-
brane were stained with methanol and 0.1% crystal vio-
let, imaged, and counted using an IX71 inverted
microscope (Olympus, Tokyo, Japan). Experiments were
independently repeated three times.
Bioinformatics methods
The miRNA targets predicted by computer-aided algo-
rithms were obtained from pictar (http://pictar.mdc-berlin.
de/cgi-bin/new_PicTar_vertebrate.cgi.), targetscan (http://
www.targetscan.org) and mirbase targets (http://microrna.
sanger.ac.uk/cgi-bin/targets/v5/search.pl).
Plasmid constructs and luciferase assay
To construct a luciferase reporter vector, HOXA5 3’-
UTR fragment containing putative binding sites for miR-
196a was amplified by PCR using the following primers:
sense-5’-GATGTTTTAACTTATTTATATGAAG-3’ and
reverse-5’-CAA ATATTGTCCAAGTCTGGCTGTT-3’.
The PCR product was subcloned downstream of the luci-
ferase gene in the pLUC Luciferase vector (Ambion, Inc.,
Austin, TX, USA) and named HOXA5-3’-UTR-WT. Site-
directed mutagenesis of the miR-196a target site in the
HOXA5-3’-UTR was performed using the Quick-change
mutagenesis kit (Stratagene, Heidelberg, Germany) and
named HOXA5 -3’-UTR-Mut, in which 3’-UTR-WT was
used as a template. For the mutated construct, the miR-
196a target site 5’- GATATTTTTATTCAAA CTACCTA
-3’ was substituted with a 5’- GATATTTTTATTCTTT
GATGGAA -3’ fragment.
Human HEK293T cells grown in a 48-well plate were
co-transfected with 200 ng of either mock pCDNA/
miR-NC or pCDNA/miR-196a, 10 ng of firefly luciferase
reporter comprising wild type or mutant 3’UTR of
HOXA5 gene, and 2 ng of pRL-TK (Promega, Madison,
WI, USA) using Lipofectamie 2000 ( Invitrogen, USA).
Cells were harvested 48 h after transfection for luciferase
assay using a luciferase assay kit (Promega) according to
the manufacturer’s protocol. Each experiment was
repeated triplicates.
Western blotting assay
Cells were lysed using mammalian protein extraction re-
agent RIPA (Beyotime) supplemented with protease inhi-
bitors cocktail (Roche) and PMSF (Roche). Protein
concentration was measured with the Bio-Rad protein
assay kit. 50 μg protein extractions were separated by12% SDS-polyacrylamide gel electrophoresis (SDS-
PAGE), then transferred to 0.22 μm NC membranes
(Sigma)and incubated with specific antibodies. Autora-
diograms were quantified by densitometry (Quantity
One software; Bio-Rad). GAPDH was used as control.
GAPDH antibody and goat anti-HOXA5 (1:200) were
purchased from sigma and Santa Cruz Biotechnology
(Santa Cruz, CA, USA), respectively.
Statistical analysis
Student’s t-test (two-tailed), One-way ANOVA and
Mann–Whitney test were performed to analyze the data
using SPSS 16.0 software. P values less than 0.05 were
considered statistically significant.
Results
miR-196a expression is up-regulated in human NSCLC
tissues
The level of miR-196a was detected in 34 NSCLC sam-
ples and adjacent, histologically normal tissues by qRT-
PCR, and normalized to U6. miR-196a expression was
significantly up-regulated in cancerous tissues (median
ratio of 22.9-fold, p < 0.01) compared with corresponding
normal tissues. Furthermore, analysis of the correlation
of miR-196a expression with clinical pathological fea-
tures of NSCLC patients, revealed a significant associ-
ation between miR-196a up-regulation and advanced
pathological stage (I/II, n= 20) vs (III/IV, n= 14) and
NSCLC lymph-node metastasis (Figure 1A). We next
performed qRT-PCR analysis to examine the expression
of miR-196a in five human NSCLC cell lines, including
both adenocarcinoma and squamous carcinoma sub-
types. Of these, four cell lines (SPC-A1, NCI-H1650,
NCI-H1299 and SK-MES-1) expressed higher levels of
miR-196a compared with the normal, bronchial epithe-
lial cell line, 16HBE, while A549 cells expressed rela-
tively low endogenous levels of miR-196a (Figure 1B).
These results indicate that over-expression of miR-196a
may play an important role in NSCLC progression and
development.
Effect of DNA methylation on miR-196a expression
Since the expression of miR-196a was frequently up-
regulated in NSCLC, we investigated whether this might
be mediated by epigenetic mechanisms, including DNA
demethylation. We hypothesized that epigenetic modifi-
cation of CpG-rich regions within the regulatory regions
of miR-196a may be involved in aberrant transcriptional
activation. Bioinformatic analysis identified a canonical
CpG island in the promoter region of the miRNA-196a-
1 loci (Figure 2A); however, no canonical CpG island
was found in the promoter region of the miRNA-196a-2
loci (data not shown). Following treatment of 16HBE
cells with DNA demethylating agent (5-aza-CdR), the
Figure 1 qRT-PCR analysis of miR-196a in NSCLC tissues and matched normal tissues. (A) Determining miR-196a expression in NSCLC
tissues and its clinical significance. miR-196a was detected in 34 pairs of NSCLC tissues by qRT-PCR. Data are presented as fold-changes in tumor
tissues relative to normal tissues. miR-196a expression was significantly higher in patients with a higher pathological stage and lymph-node
metastasis. (B) Analysis of miR-196a expression levels in NSCLC cell lines (A549, SPC-A1, NCI-H1650, NCI-H1299 and SK-MES-1) compared with the
normal bronchial epithelial cell line (16HBE) by qRT-PCR. (C) Analysis of miR-196a expression following treatment of SPCA1 cells with anti-miR-NC or
miR-196a inhibitors by qRT-PCR. (D) Analysis of miR-196a expression following treatment of A549 cells with miR-NC, miR-196a mimics, pCDNA-NC or
pCDNA-miR-196a by qRT-PCR. All experiments were performed in biological triplicate with three technical replicates. *P < 0.05, **P< 0.01.
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(Figure 2B) and CpG island methylation was assessed by
bisulfite sequencing (Figure 2C). We found that miR-
196a expression was significantly increased 4.4- or 5.1-
fold in 5-aza-CdR treated cells compared with control,
and the frequency of methylation was decreased from
78.2% to 67%. These results indicate that up-regulation
of miR-196a in NSCLC cells may be affected by DNA
demethylation.
Manipulation of miR-196a levels in NSCLC cells
To selectively down-regulate or over-express miR-196a,
miR-196a inhibitors or mature miR-196a mimics and
their corresponding negative controls (anti-miR-NC or
miR-NC, respectively) were transiently transfected into
SPC-A1 or A549 cells. In addition, to stably sustain the
expression of miR-196a in A549 cells, cells were trans-
fected with pCDNA/miR-196a vector or pCDNA/
miR-NC empty vector control. qRT-PCR analysis of
miR-196a levels was performed 48 h post-transfection,
and revealed that miR-196a expression was reduced0.52-fold following transfection with miR-196a inhibitors
and increased 24.7-fold after transfection with miR-196a
mimics. Expression of miR-196a was induced 12.2-fold in
stably transfected A549/miR-196a cells, compared with
control (Figure 1C and 1D).Effect of miR-196a on cell proliferation and apoptosis
To assess the biological role of miR-196a in NSCLC, we
investigated the effect of targeted knockdown or overex-
pression of miR-196a on cell proliferation and apoptosis.
MTT assay revealed that cell growth was significantly
impaired in SPC-A1 cells transfected with miR-196a
inhibitors, while proliferation of A549 cells was
increased in pCDNA/miR-196a transfected cells com-
pared with controls (Anti-miR-NC or pCDNA/miR-NC,
respectively) (Figure 3A and 3B). Similarly, the results of
colony-formation assays revealed that clonogenic sur-
vival was decreased following inhibition of miR-196a in
SPC-A1 cells, and enhanced in pCDNA/miR-196a trans-
fected A549 cells (Figure 3C and 3D).
Figure 2 Analysis of the correlation between methylation status and expression of miR-196a. (A) Map of the CpG island position of
miR-196a-1. Vertical ticks mark CpG sites. (B) The level of miR-196a expression in 16HBE cells after treatment of 5-aza-dC (0, 2, 5 μM). (C) The
methylation status of the CpG island of miR-196a-1 was assessed by bisulfite sequencing before and after 5-aza-dC treatment in 16HBE cells.
Open and filled squares denote unmethylated and methylated CpG sites, respectively. Each row represents a single clone. *P < 0.05; **P < 0.01.
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factor to cell growth inhibition, we performed Hochest
staining and flow-cytometric analysis of SPC-A1 cells
after transfection with miR-196a inhibitors. Alteration of
miR-196a expression had no significant effect on cell
apoptosis compared with control cells (data not shown).
Taken together, these results indicate that inhibition of
miR-196a suppresses cell growth, but is not associated
with induction of apoptosis.
miR-196a promotes migration and invasion of NSCLC
cells
Cell invasion is a significant aspect of cancer progres-
sion, and involves the migration of tumor cells into con-
tiguous tissues and the dissolution of extracellular
matrix proteins. To investigate whether miR-196a had a
direct functional role in facilitating NSCLC cell migra-
tion and invasion, we evaluated cancer cell invasion
through Matrigel and migration through a transwell. As
shown in Figure 4A, inhibition of miR-196a impeded the
migration of SPC-A1 cells by approximately 64% com-
pared with control. Similarly, invasion of SPC-A1 cells
was also reduced 59% following inhibition of miR-196a.
Conversely, transfection of A549 cells with miR-196amimics promoted cell migration and invasion ability
~2.5-fold (Figure 4B). These data indicate that miR-196a
is an onco-miRNA that can promote the migratory and
invasive phenotype of NSCLC cells.
HOXA5 is a direct target of miR-196a
To explore the molecular mechanism by which miR-
196a contributes to the proliferation and invasion of
NSCLC cells, we searched for potential targets as pre-
dicted by commonly cited programs such as TargetScan,
PicTar and miRanda. Two candidate genes, HOXA5 and
FOXO1, were selected for further analysis, owing to their
relatively high prediction score and their complementary
structure with miRNA-196a (Figure 5A). To verify
whether these genes were direct targets of miR-196a, the
wild-type 3’ untranslated region (UTR) of HOXA5 and
FOXO1 were fused directly downstream of the firefly
luciferase gene (pLuc). pCDNA/miR-196a was then co-
transfected with various luciferase 3’ UTR constructs
into HEK293T cells. MiR-196a significantly inhibited
luciferase activity (~45%) of the wild-type pLuc-HOXA5
3’UTR reporter.
To further confirm that miR-196a-mediated reduction
of luciferase activity from the pLuc-HOXA5 3’-UTR
Figure 3 Effect of miR-196a on cell proliferation in vitro. (A, B) SPC-A1 cells were transfected with miR-196a inhibitors or anti-miR-NC, and
A549 cells were transfected with pCDNA/miR-196a or pCDNA/miR-NC. MTT assay was performed to determine the proliferation of SPC-A1 or
A549 cells. Data represent the mean± S.D. from three independent experiments. (C, D) Colony-forming growth assays were performed to
determine the proliferation of SPC-A1 or A549 cells. The colonies were counted and captured. *P < 0.05, **P < 0.01.
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and its putative binding site, we mutated the miR-196a
binding site by site-directed mutagenesis, resulting in
pLuc-HOXA5-3’-UTR-Mut. As expected, suppression
of luciferase activity was completely abolished in this
mutant construct compared with wild-type vector
(Figure 5B).
We next investigated whether miR-196a could regu-
late HOXA5 at both mRNA and protein levels. miR-196a inhibitors or mimics were transfected into
NSCLC cell lines, and the levels of HOXA5 mRNA
and protein were monitored (Figure 5C and 5D). qRT-
PCR analysis revealed that inhibition of miR-196a in
SPC-A1 cells led to increased expression of endogen-
ous HOXA5 mRNA compared with control. Addition-
ally, western blot analysis showed that HOXA5 protein
expression was clearly up-regulated following transfec-
tion of SPC-A1 cells with miR-196a inhibitors. In
Figure 4 Effect of miR-196a on cell migration and invasion in vitro. (A, B) SPC-A1 cells were transfected with miR-196a inhibitors or
anti-miR-NC, and A549 cells were transfected with miR-196a mimics or miR-NC. Transwell assays were performed to investigate the migratory and
invasive ability of NSCLC cells. *P < 0.05 and **P < 0.01.
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cells triggered a significant silencing effect on en-
dogenous HOXA5 expression, both at the mRNA and
protein level.
Effect of HOXA5 on NSCLC cells proliferation and invasion
To determine whether HOXA5 could also inhibit
NSCLC cell proliferation, migration and invasion, we
performed targeted knockdown of HOXA5 expression
using RNAi in A549 cells. The expression levels of
HOXA5 mRNA and protein in A549/si-HOXA5 cellswere significantly decreased compared with si-NC
transfected cells (Figure 6A). Transwell migration
assays revealed that inhibition of HOXA5 promoted
cell migration and invasion (Figure 6B). Next, we per-
formed MTT and colony formation assays to investi-
gate cell growth and clonogenicity. A549 cells
transfected with si-HOXA5 displayed a significantly
enhanced growth ability compared with cells trans-
fected with si-NC (Figure 6C, D). These data indicate
that down-regulation of HOXA5 expression promotes
NSCLC cell proliferation, migration and invasion,
Figure 5 miR-196a directly targets the HOXA5 gene. (A) A human HOXA5 or FOXO1 3’ untranslated region (UTR) fragment containing the
wild-type or mutant miR-196a binding sequence was cloned downstream of the luciferase reporter gene. (B) The luciferase reporter plasmid
containing wild-type or mutant HOXA5 and FOXO1 3’UTR were co-transfected into HEK-293 T cells with pCDNA-miR-196a or pCDNA-miR-NC.
Luciferase activity was determined using the dual luciferase assay and shown as the relative firefly activity normalized to renilla activity.
(C) qRT-PCR analyses of HOXA5 mRNA level following treatment of SPCA1 cells with miR-196a inhibitors or A549 cells with miR-196a mimics.
(D) Western blot analyses of HOXA5 protein levels following treatment of SPCA1 cells with miR-196a inhibitors or A549 cells with miR-196a
mimics. GAPDH was used as control. *P < 0.05, **P < 0.01 and N.S. not significant.
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A549 cells.
Downregulation of HOXA5 is inversely correlated with
miR-196a expression in NSCLC
As miR-196a was over-expressed in NSCLC and targeted
HOXA5 by binding to its 3’UTR, we next determinedwhether HOXA5 expression was negatively associated
with miR-196a levels in primary NSCLC patient tissues.
Analysis of HOXA5 expression level in 34 NSCLC tis-
sues and corresponding normal tissues by qRT-PCR
revealed that HOXA5 was significantly down-regulated
in NSCLC (Figure 6E). Furthermore, bivariate correl-
ation analysis revealed that low expression of HOXA5
Figure 6 Effect of HOXA5 on NSCLC cell proliferation, migration and invasion. (A) A549 cells were transfected with si-HOXA5 or si-NC, and
HOXA5 mRNA and protein levels were assessed by qRT-PCR and western blot. (B) Transwell assays were performed to investigate the migratory
and invasive ability of NSCLC cells. (C, D) MTT assay and colony-forming growth assays were performed to determine the proliferation of si-NC or
si-HOXA5 A549 cells. (E) The level of HOXA5 mRNA in NSCLC tissues was analyzed by qRT-PCR. (F) Analysis of the relationship between miR-196a
expression and HOXA5 mRNA levels. *P < 0.05, **P < 0.01.
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(Figure 6F), suggesting that the downregulation of
HOXA5 may be due to enhanced miR-196a expression
in NSCLC.
Discussion
The aberrant expression of miR-196a is a frequent event
in various cancers, suggesting that miR-196a may play
an important role in tumorigenesis and tumor progres-
sion. Indeed, several key oncogenic functions have been
attributed to miR-196a in the context of tumorigenesis.
In esophageal cancer, miR-196a over-expression pro-
motes cell proliferation, anchorage-independent growthand suppresses apoptosis by directly regulating ANXA1
[16]. In colorectal cancer, high levels of miR-196a were
observed to activate the Akt signaling pathway, promote
cancer cell detachment, migration, invasion and chemo-
sensitivity, and increase the development of lung metas-
tases in mice [10,17]. In previous studies from our
group, we reported that aberrant over-expression of
miR-196a and the resultant down-regulation of its target
p27kip1, contributes to gastric carcinogenesis [11]. We
also analyzed miRNA expression profiles in NSCLC pa-
tient tissues by miRNA microarray, and identified miR-
196a as the most highly up-regulated miRNA compared
with corresponding normal tissues [12]. Inspired by the
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miR-196a and explored the molecular mechanisms by
which miR-196a modulates the behavior of NSCLC cells.
In this study, we first examined the expression of miR-
196a in 34 paired normal/tumor tissues from NSCLC
patients, and then investigated the clinical implications.
Consistent with our previous microarray analysis, miR-
196a was dramatically upregulated in NSCLC tissues.
Specifically, miR-196a expression was significantly
higher at later stages of NSCLC development or in spe-
cimens displaying more extensive metastasis compared
with their normal counterparts. This suggests that high
expression of miR-196a may be involved in NSCLC car-
cinogenesis. In addition, we demonstrate that miR-196a
expression is elevated in NSCLC cell lines compared
with the 16HBE normal human bronchial epithelial cell
line, with the exception of A549 cells. We also show that
DNA demethylation may underlie the aberrant expres-
sion of miR-196a in NSCLC, and these findings are cur-
rently under further investigation in our laboratory.
To assess the role of miR-196a in NSCLC, we investi-
gated the gain-or-loss of function effects of miR-196a on
various aspects of NSCLC biology. First, we demon-
strated that targeted knock-down of miR-196a expres-
sion in SPC-A1 cells led to significant inhibition of cell
proliferation, migration and invasion. Conversely, intro-
ducing miR-196a into A549 cells, which express rela-
tively low levels of endogenous miR-196a, induced
corresponding malignant tumor cell behaviors. However,
unlike previous descriptions in breast cancer, alteration
of miR-196a expression did not impact apoptosis in
NSCLC cells. Therefore, the functional role of miR-196a
may be tissue- and cell type-specific, and the detailed
mechanisms of miR-196a and its targets are worthy of
further study.
Identification of putative miRNA targets is important
for a complete understanding of the specific functions of
miRNAs. In this study, we identify HOXA5 as a direct
target of miR-196a, and demonstrate that upregulation
of miR-196a significantly reduces HOXA5 expression at
both transcriptional and protein level in NSCLC cells.
Mammals have four HOX gene clusters (HOX A-D),
which act as master regulators that specify body pattern-
ing during embryonic development. As transcription fac-
tors, HOX proteins control a battery of target genes
encoding cellular functions required for cell identity, cell
growth and differentiation, as well as cell–cell and cell–
matrix interactions [19-22]. Deregulation of HOX genes
in cancer is now well established, although in general ra-
ther less is known about their function [23-28]. The
homeobox protein, HOXA5, has been shown to partici-
pate in the developmental regulation of the lung. Man-
deville et al. observed impaired postnatal lung
development in HOXA5−/− mice, indicating that HOXA5has a critical role in lung ontogeny, and implying its in-
volvement in lung maturation and function [29]. Simi-
larly, Packer et al. reported that HOXA5 is likely to be
involved in development and patterning of the mouse
lung [30]. Moreover, dysregulation of HOXA5 expres-
sion has been associated with lung tumorigenesis and
other diseases in humans [26,31]. In breast cancer,
down-regulation of HOXA5 may impact p53 gene ex-
pression, contributing to the oncogenic process [32,33].
Additionally, induction of HOXA5 is important for ret-
inoic acid (RA)-mediated apoptosis and cellular growth
inhibition acting directly downstream of RARβ, and
plays an important role in RA-mediated anti-cancer ac-
tivity [34,35].
Currently, the role of HOXA5 in NSCLC has not been
well established. Our results reveal that inhibition of
HOXA5 expression in A549 cells significantly promotes
cell proliferation, migration and invasion, consistent with
the results of ectopic miR-196a expression in the same
cells. Furthermore, our observation of a correlation be-
tween elevated miR-196a levels and decreased HOXA5
levels in NSCLC tissues, indicates that down-regulation
of HOXA5 may be a mechanism by which miR-196a
exerts its oncogenic functions.
While our study provides critical insight into NSCLC
pathogenesis, the existence of several limitations should
be noted. First, as the number of tissue samples in this
study was limited, further investigation of a larger pa-
tient cohort is essential to confirm the clinical signifi-
cance of miR-196a. Second, to further understand the
biological role of miR-196a in regulating NSCLC devel-
opment and progression, a series of in vivo studies
using xenograft models are required. Third, many stud-
ies have clearly indicated that one miRNA is capable of
controlling multiple genes. Therefore, the observed
miR-196a-mediated inhibition of cell growth and inva-
sion is likely due to simultaneous targeting of multiple
targets in NSCLC. Further studies of miR-196a will un-
doubtedly enhance our knowledge of how miR-196a
functions in regulating NSCLC cell growth and
metastasis.Conclusions
In summary, we demonstrate that miR-196a over-
expression is a common event underlying NSCLC, and
may function as an oncogene by directly targeting
HOXA5. We show, possibly for the first time, that the
miR-196a/HOXA5 axis regulates the proliferation and
invasion of NSCLC cells. These findings may help us to
better understand the pathogenesis and development of
NSCLC and facilitate the development of miRNA-
directed diagnostics and therapeutics against this deadly
disease.
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